FVIIIFactor VIII (blood clotting)
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
The SB-525 covers a recombinant adeno-associated virus serotype six vector, which encodes the complementary deoxyribonucleic acid for B domain deleted human FVIII. Its transcriptional cassette merges multi-factorial modifications to the liver-specific promoter module, FVIII transgene, synthetic polyadenylation signal and vector backbone sequence.
Inhibitor development remains a serious treatment complication of haemophilia A, particularly in PUPs, with up to 35% of PUPs developing inhibitors to FVIII.
In the treatment, we consulted the hematology department and conducted a pharmacokinetic experiment of coagulation factor (preexperiment) infusion of FVIII 40-50 U/kg.
Deficiency of clotting protein called factor VIII (FVIII) results in one of most common congenital bleeding disorders termed as Haemophilia A.
When VESCs collected from healthy mice were injected into mice with hemophilia A, the cells began generating new liver blood vessels--and the level of FVIII in the blood shot up, from less than one percent of normal to over 60 percent.
One maybe tempted to assume that ABO blood type and body weight may be biologically related probably through a pathway that involves thrombotic factors like FVIII because it is known for example, that non-blood group O individuals have higher FVIII.
On the 4th day after admission to hospital, aPTT cross-mixing test revealed a reduction in factor VIII (FVIII) activity levels (9%).
In a previous manuscript published6, we founded that individuals who were non-O had a higher risk of thrombosis (OR:2.6) and higher FVIII levels (over 232%) indicating that FVIII is an independent risk factor of thrombosis.
The treatment of hemophilia may involve prophylaxis, management of bleeding episodes, treatment of factor VIII (FVIII) inhibitors, and treatment and rehabilitation of hemophilia synovitis.
Jayandharan G et al analysed DNA from 109 unrelated Indian patients with Haemophilia A (HA) for their FVIII gene defects.
Prophylactic FVIII replacement is preferred to on-demand therapy because it reduces the frequency of bleeds and prevents the development of chronic arthropathy in the long term.